Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

TAK-071

Generic Name: TAK-071

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of TAK-071 in People With Parkinson Disease

Phase 2

Completed

Posted: 2020/04/06

Sponsor:Takeda

ID:NCT04334317

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Phase 1

Terminated

Posted: 2016/09/28

Sponsor:Takeda

ID:NCT02918266

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Phase 1

Terminated

Posted: 2016/05/11

Sponsor:Takeda

ID:NCT02769065

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

TAK-071 Shows Mixed Results in Parkinson's Disease Trial: Cognitive Benefits Observed Despite Missing Primary Endpoint

5 months ago

A Phase 2 clinical trial evaluating TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, failed to demonstrate superiority over placebo in improving gait variability in Parkinson's disease patients.

Device-Assisted Dopamine Therapy and TAK-071 Show Promise in Parkinson's Disease

8 months ago

A device-assisted therapy delivering dopamine directly to the brain shows potential in treating Parkinson's disease by improving symptom control without dyskinesia.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy